The Claim

Liraglutide 3.0 mg improves inhibitory control in obese adults, as evidenced by a greater proportion of successful stops on the stop-signal task, although stop-signal reaction time did not show a statistically significant change.

Source: Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies

What the research says

Not yet evaluated

We are still looking at what the research says.

Supports
0score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
0 studies reviewed
In plain English

Taking the drug liraglutide at 3.0 mg might help people with obesity better control their impulses, like stopping themselves from doing something quickly, even if their reaction speed didn't clearly improve.

See the scientific wording

Liraglutide 3.0 mg improves inhibitory control in obese adults, as shown by a greater proportion of successful stops on the stop-signal task, though stop-signal reaction time did not reach significance.

Score breakdown, mechanism chain, raw evidence, ideal studies needed

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.